本期看點

1. Genmab公司旗下抗體偶聯藥物（ADC）rinatabart sesutecan用以治療復發性/晚期子宮內膜癌的早期臨床試驗結果積極，低劑量組患者的疾病控制率（DCR）達100%。

2. γ9δ2 T細胞激活劑ICT01聯用阿扎胞苷和維奈托克（Aza-Ven）治療不適合強化化療的新確診的急性髓系白血?。ˋML）患者，在一項1/2期臨床試驗中的復合完全緩解（CRc）率達96%。

3. 個體化癌癥疫苗SV-102治療轉移性去勢抵抗性前列腺癌（mCRPC）的1期臨床試驗表現亮眼，客觀緩解率（ORR）達87%，完全緩解（CR）率為53%。

Rinatabart sesutecan：公布1/2期臨床試驗數據

Genmab公司日前披露旗下的候選療法rinatabart sesutecan（Rina-S）在1/2期試驗中，用以治療復發性/晚期子宮內膜癌患者中的療效結果。Rina-S是一種潛在“best-in-class”、葉酸受體α（FRα）靶向ADC，Genmab在去年4月收購普方生物（ProfoundBio）時獲得此款療法。

截至2024年11月22日，64例接受過大量既往治療的子宮內膜癌患者（中位3線，范圍1-8）接受了100 mg/m2（n=22）或120 mg/m2（n=42）劑量的Rina-S治療。在療效可評估患者中，中位治療持續時間為18.7周。分析顯示，接受低（n=22）與高（n=33）劑量患者的未確認ORR分別為50%與45.5%，其中低劑量組包含2例CR。低與高劑量組患者的DCR則分別為100%和81.8%。此外，在低與高劑量組中，分別有81.8%（9/11）與80.0%（12/15）患者持續緩解。安全性方面，最常見（>25%）的治療伴發不良事件（TEAE）在不同劑量下相似，主要是血細胞減少癥和1-2級胃腸道事件（惡心、嘔吐、食欲下降）。

ICT01：公布1/2期聯合治療試驗數據

ImCheck Therapeutics公司公布了其新型γ9δ2 T細胞激活劑ICT01聯用Aza-Ven治療不適合強化化療的新確診AML患者的積極1/2期臨床試驗數據。γ9δ2 T細胞是先天免疫系統的一部分，負責對腫瘤和感染的免疫監察。ICT01是一款靶向嗜乳脂蛋白家族成員BTN3A的單克隆抗體療法，通過與BTN3A結合，它可以選擇性地激活γ9δ2 T細胞，并且促進它們遷移和浸潤腫瘤，進一步激發CD8陽性T細胞和自然殺傷細胞的抗腫瘤反應。

截至2025年1月20日的數據，接受推薦劑量的ICT01聯合治療的患者的CRc率為96%，CR率為74%，且各種分子亞型的患者均有緩解。值得注意的是，具有不良或中等風險突變的患者通常對Aza-Ven治療應答較低，但接受三聯療法治療的患者實現了高緩解率，例如TP53突變AML患者的CR和CRc率分別達到了60%和83%。此外，接受10 mg ICT01治療的患者初步的9個月總生存率為83%。安全性方面，三聯療法在臨床上具有良好的可控性。

SV-102：公布1期臨床試驗數據

Syncromune公司公布了其個體化癌癥疫苗SV-102在mCRPC患者中的1期臨床試驗結果。數據表明，接受SV-102治療患者的ORR為87%，53%的患者達到了CR。安全性方面，SV-102耐受性良好，觀察到的TEAE多為低級別。

ORIC-944：公布1b期聯合治療試驗的初步數據

ORIC Pharmaceuticals公司公布了其選擇性PRC2別構抑制劑ORIC-944聯用雄激素受體（AR）抑制劑治療mCRPC的1b期臨床試驗的初步數據。截至2025年5月9日的數據，59%（10/17）的患者達到PSA50應答（即前列腺特異性抗原水平降低50%），確認的PSA50應答率為47%（1例待確認），24%（4/17）的患者達到確認的PSA90應答。在所有ORIC-944劑量水平中均觀察到PSA應答，目前大多數患者仍在繼續治療，其中多名患者的治療時間已接近一年或更長。安全性方面，ORIC-944與apalutamide或darolutamide聯合使用的耐受性普遍良好，絕大多數不良事件為1/2級，與PRC2和AR抑制一致。

STX-001：公布1期臨床試驗的初步數據

Strand Therapeutics公司公布了其自我復制mRNA療法STX-001用于治療晚期實體瘤的1期臨床試驗結果。STX-001是一種脂質納米顆粒封裝的自我復制mRNA藥物，可激活先天免疫系統，促進免疫原性癌細胞死亡，并表達IL-12以誘導針對腫瘤的免疫反應。在臨床前模型中，STX-001表現出顯著的免疫調節和抗腫瘤活性。

從2024年5月29日至數據截止日期（2024年12月16日），5名完成評估的黑色素瘤患者中，有3人的非注射病灶縮?。催h隔效應），其中1例達到確認的CR，1例達到部分緩解（PR），1例靶病灶縮小100%，多個皮膚/內臟病灶出現顯著的炎癥反應。STX-001顯示出初步良好的療效、強烈的免疫激活作用以及可控的安全性。這些結果支持其作為單藥療法以及與免疫檢查點抑制劑聯合使用的進一步開發。

參考資料（可上下滑動查看）

[1] ????, 'TGF-β2 ASO' ??? 1? "?? IND ??". Retrieved May 30, 2025, from https://www.biospectator.com/news/view/25209

[2] Syncromune? Inc. Announces Publication of Abstract on SYNC-T? Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting. Retrieved May 30, 2025, from https://syncromune.com/2025/05/23/syncromune-inc-announces-publication-of-abstract-on-sync-t-therapy-sv-102-phase-1-data-for-metastatic-prostate-cancer-at-asco-2025-annual-meeting/

[3] Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting. Retrieved May 30, 2025, from https://autobahntx.com/news/autobahn-therapeutics-announces-presentation-of-abx-002-phase-1-clinical-results-at-the-2025-ascp-annual-meeting/

[4] Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis. Retrieved May 30, 2025, from https://immixbio.com/immix-biopharma-announces-positive-results-for-nxc-201-at-asco-oral-presentation-enabling-pathway-to-best-in-class-therapy-for-relapsed-refractory-al-amyloidosis/

[5] AbelZeta Presents New Data on C-CAR168 for the Treatment of Autoimmune Diseases at LUPUS 2025. Retrieved May 30, 2025, from https://www.prnewswire.com/news-releases/abelzeta-presents-new-data-on-c-car168-for-the-treatment-of-autoimmune-diseases-at-lupus-2025-302463558.html

[6] ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025. Retrieved May 30, 2025, from https://www.globenewswire.com/news-release/2025/05/22/3087173/0/en/ImCheck-Reports-High-Remission-Rates-in-AML-Patients-with-ICT01-Combination-Therapy-at-ASCO-2025.html

[7] Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025. Retrieved May 30, 2025, from https://www.globenewswire.com/news-release/2025/05/22/3087166/0/en/Boehringer-Ingelheim-to-present-early-clinical-evidence-of-innate-immune-modulation-and-anti-tumor-activity-via-SIRP%CE%B1-blockade-in-two-ongoing-trials-at-ASCO-2025.html

[8] Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies. Retrieved May 30, 2025 from https://www.globenewswire.com/news-release/2025/05/29/3090174/0/en/Auron-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-AUTX-703-in-Advanced-Hematologic-Malignancies.html

[9] Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Retrieved May 24, 2025 from https://ir.genmab.com/news-releases/news-release-details/genmab-highlight-new-data-evaluating-late-stage-oncology

[10] Navigator Medicines Announces First Participants Dosed in a Phase 1b Trial of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases. Retrieved May 30, 2025 from https://www.businesswire.com/news/home/20250529174222/en/Navigator-Medicines-Announces-First-Participants-Dosed-in-a-Phase-1b-Trial-of-NAV-240-a-Potential-Best-in-Class-Anti-OX40L-and-Anti-TNF-Bispecific-Antibody-Therapeutic-for-Autoimmune-Diseases

[11] Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting. Retrieved May 23, 2025, from https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-and-kyowa-kirin-announce-pivotal-monotherapy-data

[12] Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025. Retrieved May 23, 2025 from https://www.globenewswire.com/news-release/2025/05/22/3087169/0/en/Cullinan-Therapeutics-Taiho-Pharmaceutical-and-Taiho-Oncology-to-Present-Positive-Results-from-Pivotal-Phase-2b-REZILIENT1-Trial-of-Zipalertinib-at-ASCO-2025.html

[13] Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis. Retrieved May 30, 2025 from https://www.globenewswire.com/news-release/2025/05/27/3088623/0/en/Palisade-Bio-Reports-Positive-Phase-1a-Results-for-PALI-2108-a-First-in-Class-Terminal-Ileum-and-Colon-Targeted-PDE4-B-D-Inhibitor-for-Fibrostenotic-Crohn-s-Disease-and-Ulcerative-.html

[14] AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders. Retrieved May 30, 2025 from https://www.globenewswire.com/news-release/2025/05/27/3088653/0/en/AskBio-Announces-Publication-of-Complete-Results-of-Phase-1b-Trial-of-AB-1005-Gene-Therapy-in-Participants-with-Parkinson-s-Disease-in-Movement-Disorders.html

[15] Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at the American Society of Clinical Oncology - Annual Meeting 2025. Retrieved May 30, 2025 from https://www.prnewswire.com/news-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology---annual-meeting-2025-302465586.html

[16] IRLAB reports positive results from the second part of a Phase I study with IRL757. Retrieved May 30, 2025 from https://irlab.se/mfn_news/irlab-reports-positive-results-from-the-second-part-of-a-phase-i-study-with-irl757/

[17] Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping. Retrieved May 30, 2025 from https://www.globenewswire.com/news-release/2025/05/28/3089307/0/en/Entrada-Therapeutics-Receives-Authorization-in-the-European-Union-to-Initiate-ELEVATE-45-201-a-Phase-1-2-Multiple-Ascending-Dose-Clinical-Study-of-ENTR-601-45-in-Patients-Living-wi.html

[18] Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients (pts) with advanced solid tumors. Retrieved May 30, 2025 from https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.9556

[19] ORIC? Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC. Retrieved May 30, 2025 from https://www.globenewswire.com/news-release/2025/05/28/3089929/0/en/ORIC-Pharmaceuticals-Announces-Potentially-Best-In-Class-Preliminary-Efficacy-and-Safety-Data-from-Ongoing-Phase-1b-Trial-of-ORIC-944-in-Combination-with-AR-Inhibitors-for-the-Trea.html

[20] AKTIS ONCOLOGY INITIATES PHASE 1B CLINICAL TRIAL OF ITS NECTIN-4-TARGETING RADIOPHARMACEUTICAL PRODUCT CANDIDATE, AKY-1189, ACROSS MULTIPLE TUMOR TYPES. Retrieved May 30, 2025 from https://www.prnewswire.com/news-releases/aktis-oncology-initiates-phase-1b-clinical-trial-of-its-nectin-4-targeting-radiopharmaceutical-product-candidate-aky-1189-across-multiple-tumor-types-302466453.html

[21] Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis. Retrieved May 30, 2025 from https://www.businesswire.com/news/home/20250528125414/en/Enveda-Reports-Favorable-Phase-1-Safety-for-Novel-Oral-Anti-Inflammatory-Launches-Phase-1b-Trial-in-Atopic-Dermatitis

[22] Phanes Therapeutics announces first patient dosed in clinical study of mavrostobart (PT199) in combination with chemotherapy. Retrieved May 30, 2025 from https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-mavrostobart-pt199-in-combination-with-chemotherapy-302464552.html

[23] TIXiMED Announces Successful Completion of a Phase 1 Study of its Novel Oral Disease-Modifying Type 1 Diabetes Therapy. Retrieved May 30, 2025 from https://www.businesswire.com/news/home/20250529307401/en/TIXiMED-Announces-Successful-Completion-of-a-Phase-1-Study-of-its-Novel-Oral-Disease-Modifying-Type-1-Diabetes-Therapy

免責聲明：藥明康德內容團隊專注介紹全球生物醫藥健康研究進展。本文僅作信息交流之目的，文中觀點不代 表藥 明康德立場，亦不代 表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。